跳至主要内容
临床试验/NCT01456507
NCT01456507已完成1 期

An Open-Label, Single-Dose, Randomized, Three-Way Crossover Study in Healthy Volunteers to Estimate the Effects of Food and of Sprinkling ALO-02 Pellets on Applesauce on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Pellets-in-Capsule Formulation of Oxycodone 40 Mg With Sequestered Naltrexone 4.8 Mg

Pfizer1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2011年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
24
试验地点
1
主要终点
Area Under the Curve (AUC) to time infinity (inf) of oxycodone

研究概览

简要总结

The purpose of this study is to estimate the effects of food and of sprinkling ALO-02 pellets on applesauce on the bioavailability of oxycodone and naltrexone/6- beta-naltrexol from an extended release pellets-in-capsule formulation of oxycodone 40 mg with sequestered naltrexone 4.8 mg.

详细描述

Bioavailability

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive

排除标准

  • •Evidence or history of clinically significant diseases

研究组 & 干预措施

A

Experimental

1×40 mg ALO-02 capsule administered with 240 mL of water under fasting conditions.

干预措施: ALO-02 (Oxycodone Naltrexone) (Drug)

B

Experimental

1×40 mg ALO-02 capsule administered with 240 mL of water under fed conditions (standard high fat breakfast).

干预措施: ALO-02 (Oxycodone Naltrexone) (Drug)

C

Experimental

1×40 mg ALO-02 with the ALO-02 pellets sprinkled approximately on one table spoon of applesauce, and administered with 240 mL of water under fasting conditions.

干预措施: ALO-02 (Oxycodone Naltrexone) (Drug)

结局指标

主要结局

Area Under the Curve (AUC) to time infinity (inf) of oxycodone

时间窗: predose, 0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose

Area Under the Curve (AUC) to last quantifiable concentration (last) of oxycodone

时间窗: predose, 0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose

Maximum Plasma Concentration (Cmax) of oxycodone

时间窗: predose, 0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose

次要结局

  • Adverse events, vital signs, pulse oximetry, and safety laboratory parameters.(over 120 hours)
  • C24, Tmax (time at maximum concentration) and half-life of oxycodone, as data permit.(predose, 0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose)
  • AUClast, AUCinf, and Cmax of naltrexone and 6-beta-naltrexol, as data permit(predose, 1,2,4,8,12,24,48,120 hours post-dose)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Healthy Volunteers Study to Estimate the Effects of... | 临床试验